Skip to content

Continuous Glucose Monitoring of Late Preterm Birth After Corticosteroids

An Observational Study to Predict Neonatal Hypoglycemia Using Antenatal Continuous Glucose Monitoring Among Late Preterm Parturients Receiving Corticosteroids

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03738293
Enrollment
0
Registered
2018-11-13
Start date
2019-12-31
Completion date
2020-12-31
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Hypoglycemia, Pregnancy Preterm, Prematurity

Keywords

Steroid, Corticosteroid, Betamethasone, Preterm Birth

Brief summary

Women undergoing late preterm birth are at high risk of delivering a newborn with neonatal hypoglycemia. The investigators plan to monitor interstitial glucose levels prior to delivery in these women in order to develop a better understanding of the relationship between maternal hyperglycemia and neonatal hypoglycemia.

Interventions

None listed

Sponsors

Pediatrix
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnancy admitted to labor and delivery between 34w0d and 36w5d * English speaking women * High probability of delivery in late preterm period defined by any of the following: 1. Membrane rupture by 2 criteria (pooling, positive nitrazine, or ferning) OR leaking amniotic fluid from the cervix 2. Preterm labor with intact membrane, defined as at least 6 uterine contractions in 60 minutes and at least: cervical dilation greater than or equal to 3cm dilated OR 80% effaced OR planned delivery by induction of labor or cesarean in no less than 24 hrs and no more than 7 days, for any indication as deemed necessary by the provider * Received at least one dose of corticosteroid within twelve hours of enrollment

Exclusion criteria

* Any prior antenatal corticosteroid course in current pregnancy * Systemic corticosteroid administration during current pregnancy * Fetal demise or known major fetal anomaly, including cardiac anomaly or hydrops * Maternal contraindication to betamethasone: hypersensitivity reaction to any component of the medication, idiopathic thrombocytopenic, purpura, systemic fungal infection, or current use of amphotericin B * Diabetes, pregestational or gestational * Preexisting plan for intrapartum monitoring of maternal glucose levels for any reason * Delivery expected within 12 hours of randomization, because of insufficient time for corticosteroids to confer benefit, including: 1. Ruptured membranes with cervical dilation ≥ 3cm or with more than 6 contractions per hour unless Pitocin is deferred for at least 12 hours 2. Chorioamnionitis 3. Cervical dilation ≥ 8cm 4. Evidence of non-reassuring fetal status requiring immediate delivery * To ensure that there is an adequate proportion of women presenting at 34 to 35 weeks gestation, enrollment will be restricted so that no more than 50% of the women in the trial present at 36 weeks.

Design outcomes

Primary

MeasureTime frameDescription
Neonatal Hypoglycemia48 hoursNewborn glucose level less than 40mg/dL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026